Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2008-03-06 Declaration of Voting R…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Results of General Meeting 3 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Results of General Meeting held on 7 March 2008' and contains detailed voting results for multiple resolutions passed at a general meeting. The resolutions include election of a director and approval of share issues and options, with proxy vote counts and outcomes. This is a formal announcement of the voting results from a shareholder meeting, not the meeting materials themselves or a full report. The content matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is about 5,325 characters, which is sufficient to include detailed voting results rather than just a brief announcement or link to a report. Therefore, the correct classification is DVA with high confidence.
2008-03-06 English
Half Yearly Report and Accounts 26 pages ?Kb
Regulatory Filings
2008-02-28 English
LCT and US based Barbara Davis Center collaborate on trial 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated February 27, 2008, regarding a collaboration between Living Cell Technologies and the Barbara Davis Center to conduct a diabetes clinical trial program. It discusses the signing of a term sheet, plans for a clinical trial, and background information about the company and the partner center. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a news release or announcement about a business collaboration and clinical trial plans, not a financial report, regulatory filing, or management report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general company announcement that does not fit other specific categories.
2008-02-26 English
LCT to Present Positive Preliminary Clinical Results 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated February 13, 2008, from Living Cell Technologies Ltd. It announces that the company will present positive preliminary clinical results at an upcoming international congress. The content focuses on the announcement of a presentation of clinical trial results, not the presentation or report itself. There are no financial statements, detailed financial data, or regulatory filings included. The document is relatively short (5836 characters) and serves as a news release about an upcoming event rather than a detailed report or transcript. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement or miscellaneous filing that does not fit other categories.
2008-02-12 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, dates of transactions, and nature of the transactions (on-market transfer). This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3521 characters, which is consistent with a detailed notice of director's interest changes rather than a brief announcement or other report type. Therefore, the correct classification is DIRS (Director's Dealing).
2008-02-12 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details such as on-market transfer. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives (insider trades). The document length is 3680 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the correct classification is Director's Dealing (DIRS).
2008-02-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.